Druggability & Clinical Context
Druggability
Undruggable
Score: 0.21
Target Class
Structural Protein
Druggability Analysis
Structural Tractability0.30
Key Metrics
PDB Structures:
0
Known Drugs:
4
Approved:
2
In Clinical Trials:
0
Drug Pipeline (4 compounds)
2 Approved · 1 Preclinical
Therapeutic Areas:Alzheimer's disease and cognitive decline Schizophrenia and psychiatric disorders Neurodegeneration and neuronal protection Synaptic dysfunction and plasticity disorders Age-related cognitive impairment
Druggability Rationale: MAP6 presents low druggability due to its structural protein classification with limited known binding pockets and absence of experimental structural data (0 PDB entries), making rational drug design challenging. However, indirect modulation through microtubule stabilization is viable, as evidenced by clinical success of taxanes (paclitaxel, ixabepilone), though direct MAP6 targeting remains underdeveloped.
Mechanism: Drugs targeting MAP6 would stabilize microtubules through direct binding or modulation of MAP6's stabilizing activity, thereby promoting neuronal cytoskeletal integrity and synaptic function. This stabilization could enhance axonal transport, prevent neuronal degeneration, and support cognitive and synaptic plasticity in neurodegenerative conditions.
Drug Pipeline (4 compounds)
2 Approved · 1 Preclinical
Known Drugs:Paclitaxel (Taxol) (approved) — Cancer; investigational for neurodegeneration via microtubule stabilization
Ixabepilone (Ixempra) (approved) — Cancer; preclinical investigation for Alzheimer's disease via microtubule stabilization
MAP6-derived peptide stabilizers (preclinical) — Neurodegeneration, cognitive decline (research compounds)
Microtubule-associated protein kinase inhibitors (research) — Synaptic dysfunction, neuronal plasticity disorders (tool compounds)
Structural Data:PDB —AlphaFold ✓Cryo-EM —
Binding Pocket Analysis:No experimentally resolved binding pockets are available; AlphaFold predictions suggest intrinsically disordered regions typical of MAPs, which lack deep druggable cavities and favor protein-protein interaction or allosteric modulation strategies over traditional small-molecule binding. Druggability may be enhanced through peptide mimetics or allosteric modulators targeting MAP6's interaction surfaces with microtubules or regulatory protein partners.
Selectivity & Safety Considerations
Selectivity is a major challenge for MAP6 targeting, as stabilizing microtubules broadly affects multiple MAPs and cellular processes beyond neuronal compartments, risking off-target effects on mitotic spindle dynamics and non-neuronal tissues. Achieving MAP6-specific modulation over related microtubule-associated proteins (MAP2, MAP1, tau) would require isoform-selective binding or allosteric approaches not yet established.